Prudential PLC Reduces Stock Position in Bristol Myers Squibb Company $BMY

Prudential PLC reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 25.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 345,704 shares of the biopharmaceutical company’s stock after selling 117,602 shares during the quarter. Prudential PLC’s holdings in Bristol Myers Squibb were worth $18,647,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in BMY. Physician Wealth Advisors Inc. boosted its stake in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the 2nd quarter worth about $25,000. EQ Wealth Advisors LLC acquired a new stake in Bristol Myers Squibb in the 4th quarter worth about $32,000. Garner Asset Management Corp acquired a new stake in Bristol Myers Squibb in the 4th quarter worth about $35,000. Finally, Beacon Financial Strategies CORP acquired a new stake in Bristol Myers Squibb in the 4th quarter worth about $38,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price target on the stock. Cantor Fitzgerald raised their price target on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 8th. Wells Fargo & Company reissued an “outperform” rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 19th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $61.31.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Up 3.6%

BMY opened at $56.71 on Friday. The firm has a 50 day moving average price of $58.13 and a 200 day moving average price of $56.52. The company has a market cap of $115.81 billion, a PE ratio of 15.93, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.